Generics Bulletin Originals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
What’s Next? Five Things To Look Out For In December
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.
What’s Next? Five Things To Look Out For In November
European litigation, potential US generic launches and new CEOs are among the headlines in November – amid the ninth annual Global Generics & Biosimilars Awards, in Frankfurt.
What’s Next? Five Things To Look Out For In October
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
What’s Next? Five Things To Look Out For In September
As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.
Science-Based Thinking Promises Global Progress On Biosimilars
A science-based approach to biosimilars, exemplified by the latest statement from European regulators, makes further progress on biosimilars just a matter of time, according to Gillian Woollett, vice president and head of regulatory strategy and policy at Samsung Bioepis.
Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’
In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.
Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected
Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.
Faster And Cheaper: Similis Bio Aims To Enhance Biosimilar Development
In the wake of Similis Bio’s first biosimilar partnership, the JSR Life Sciences unit’s head, John Gabrielson, talks to Generics Bulletin about the Similis Bio model and how the firm believes it can help bring biosimilars to market more rapidly and efficiently.
Aripiprazole Returns To Lead October Rises In UK
Having led the fastest-rising average trade prices in the UK in August, aripiprazole once again topped our table of Biggest Risers in October, based on the latest figures from market researcher WaveData – but this time it was the oral solution presentation of the product that saw a spike.
Prices Double For Multiple UK Generics In September
September brought triple-digit percentage increases in the average trade price of multiple UK generics, according to the latest figures from WaveData.
Aripiprazole Leads A Slew Of UK Price Rises In A Dynamic August
Aripiprazole led the steepest UK generic price rises in August 2022, a hugely dynamic month that saw treble-digit percentage price increases for a number of molecules, according to the latest figures from WaveData.
UK Alendronate Prices Explode In July
An average price rise of over 1,400% was seen for alendronate 70mg tablets in the UK last month, as average prices for a host of other generics more than doubled.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.